BLFS

$19.40

Post-MarketAs of Mar 17, 8:00 PM UTC

BioLife Solutions, Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$19.40
Potential Upside
5%
Whystock Fair Value$20.37
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Instruments & Supplies

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used i...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$937.02M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.94
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-3.37%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
4.22

Recent News

Zacks
Mar 11, 2026

After Plunging 17.6% in 4 Weeks, Here's Why the Trend Might Reverse for BioLife Solutions (BLFS)

The heavy selling pressure might have exhausted for BioLife Solutions (BLFS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 2, 2026

Wall Street Analysts Believe BioLife Solutions (BLFS) Could Rally 35%: Here's is How to Trade

The mean of analysts' price targets for BioLife Solutions (BLFS) points to a 35% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 1, 2026

Should BioLife Solutions’ 2026 Profitability Guidance and Refocus Require Action From BLFS Investors?

BioLife Solutions, Inc. reported past fourth-quarter 2025 sales of US$24.76 million versus US$20.72 million a year earlier, with full-year 2025 revenue of US$96.21 million and a reduced net loss of US$4.60 million after its business refocus. The company also issued 2026 guidance calling for higher revenue and GAAP profitability, highlighting progress from its transformation toward higher-margin, recurring cell processing products and new collaborations. With management now targeting revenue...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Feb 27, 2026

Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million

Relay Therapeutics develops precision medicines targeting oncology and genetic diseases, leveraging proprietary computational technology.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Motley Fool
Feb 27, 2026

Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million

This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.

BEARISH
Negative press. News cycle fixated on risk factors or misses.